|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 13826 |
FusionGeneSummary for FOXO4_VAV3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: FOXO4_VAV3 | Fusion gene ID: 13826 | Hgene | Tgene | Gene symbol | FOXO4 | VAV3 | Gene ID | 4303 | 10451 |
| Gene name | forkhead box O4 | vav guanine nucleotide exchange factor 3 | |
| Synonyms | AFX|AFX1|MLLT7 | - | |
| Cytomap | Xq13.1 | 1p13.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | forkhead box protein O4fork head domain transcription factor AFX1myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 7 | guanine nucleotide exchange factor VAV3VAV-3vav 3 guanine nucleotide exchange factorvav 3 oncogene | |
| Modification date | 20180523 | 20180519 | |
| UniProtAcc | P98177 | Q9UKW4 | |
| Ensembl transtripts involved in fusion gene | ENST00000374259, ENST00000466874, ENST00000341558, | ENST00000370056, ENST00000527011, ENST00000544443, ENST00000415432, ENST00000343258, ENST00000371846, | |
| Fusion gene scores | * DoF score | 2 X 2 X 1=4 | 4 X 5 X 2=40 |
| # samples | 2 | 5 | |
| ** MAII score | log2(2/4*10)=2.32192809488736 | log2(5/40*10)=0.321928094887362 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: FOXO4 [Title/Abstract] AND VAV3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | FOXO4 | GO:0006355 | regulation of transcription, DNA-templated | 15126506 |
| Hgene | FOXO4 | GO:0007050 | cell cycle arrest | 10783894 |
| Hgene | FOXO4 | GO:0008285 | negative regulation of cell proliferation | 10783894 |
| Hgene | FOXO4 | GO:0008286 | insulin receptor signaling pathway | 10217147 |
| Hgene | FOXO4 | GO:0016525 | negative regulation of angiogenesis | 12761217 |
| Hgene | FOXO4 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 11689711|15905404 |
| Hgene | FOXO4 | GO:0051151 | negative regulation of smooth muscle cell differentiation | 16054032 |
| Hgene | FOXO4 | GO:0070317 | negative regulation of G0 to G1 transition | 10783894 |
| Hgene | FOXO4 | GO:0071158 | positive regulation of cell cycle arrest | 15905404 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | AL691579 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 3UTR-intron | ENST00000374259 | ENST00000370056 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| 3UTR-intron | ENST00000374259 | ENST00000527011 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| 3UTR-intron | ENST00000374259 | ENST00000544443 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| 3UTR-intron | ENST00000374259 | ENST00000415432 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| 3UTR-intron | ENST00000374259 | ENST00000343258 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| 3UTR-intron | ENST00000374259 | ENST00000371846 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000466874 | ENST00000370056 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000466874 | ENST00000527011 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000466874 | ENST00000544443 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000466874 | ENST00000415432 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000466874 | ENST00000343258 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000466874 | ENST00000371846 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000341558 | ENST00000370056 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000341558 | ENST00000527011 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000341558 | ENST00000544443 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000341558 | ENST00000415432 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000341558 | ENST00000343258 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
| intron-intron | ENST00000341558 | ENST00000371846 | FOXO4 | chrX | 70323213 | - | VAV3 | chr1 | 108410638 | + |
Top |
FusionProtFeatures for FOXO4_VAV3 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| FOXO4 | VAV3 |
| Transcription factor involved in the regulation of theinsulin signaling pathway. Binds to insulin-response elements(IREs) and can activate transcription of IGFBP1. Down-regulatesexpression of HIF1A and suppresses hypoxia-induced transcriptionalactivation of HIF1A-modulated genes. Also involved in negativeregulation of the cell cycle. Involved in increased proteasomeactivity in embryonic stem cells (ESCs) by activating expressionof PSMD11 in ESCs, leading to enhanced assembly of the 26Sproteasome, followed by higher proteasome activity.{ECO:0000269|PubMed:10217147, ECO:0000269|PubMed:10783894,ECO:0000269|PubMed:12761217, ECO:0000269|PubMed:15126506,ECO:0000269|PubMed:16054032, ECO:0000269|PubMed:16964248,ECO:0000269|PubMed:20874444, ECO:0000269|PubMed:22972301}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for FOXO4_VAV3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for FOXO4_VAV3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for FOXO4_VAV3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for FOXO4_VAV3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | VAV3 | C0017661 | IGA Glomerulonephritis | 1 | CTD_human |
| Tgene | VAV3 | C0020538 | Hypertensive disease | 1 | CTD_human |
| Tgene | VAV3 | C0020578 | Hyperventilation | 1 | CTD_human |
| Tgene | VAV3 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Tgene | VAV3 | C0039231 | Tachycardia | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|